Healthsonix Inc. DL-,001

erreicht werden kann ich mir ein Haus und einen Ferrari kaufen.:)

Grüße Dich Limi!  

dass dann mal so eintrifft;
und die sonne wieder  scheint,
kannste mich ja mal zu einen kl. ausflug im roten flitzer einladen.
- Käffchem  im hoffentlich dann sturmsicheren häuschen wär auch nicht schlecht.  
lg.   limi  

ein nettes Wochenende auf der Terrasse und ein wenig über Aktien lammentieren ist auf jeden Fall drin. Aber mit dem Auto nehme ich Dich net mit.*gg*  

kommt zeit kommt rat!!!
Denke mal den zustand, das die aktie bei 5 euro notiert, werden wir beide eh nicht erleben.
Mir persönlich würde 1 euro auch reichen!
*gg*  

doch, dann reichts zumindest für einen guten Wein , gell? *gg*  

wär ja allerdings nicht schlecht, petruss. Selbst kauf ich mittlerweile überhaupt nix mehr im Hot Stocks-Bereich, kaufe auch nicht nach, anderes ( OS ) läuft wesentlich besser und nervenschonender. Hoffe, daß wir hier doch noch irgendwann belohnt werden...

Wünsche Euch beiden ein recht schönes we, mit oder ohne Terrasse  :-))

mfg BoMa  

Leute die jetzt erst auf diesen Wert aufmerksam werden ,haben einfach nur Pech.Kein rankommen zur Zeit.Wollte noch welche nachpacken ,aber nix zu machen.Zum Glück schlummern schon welche im Depot.  

 

Du machst Dich aber auch ganz schön dünne zur Zeit.:)  

heimlichen Mitleser(rinen)! *gg*  

anderes hochinteressantes Betätigungsfeld gefunden, petruss :-))

Hey, Aktie steigt drüben gerade 22 % !!!   *freu*

mfg BoMa  

Möchtest Du drüber reden? :)  

das freut sich ja mein trader-depot...
und der petruss bestimmt auch...   limi  

das freut uns sicherlich alle :-)) Und das ganze drüben auch noch bei relativ guten Umsätzen... kann gerne so bleiben.

petruss, weißte doch: Reden ist Silber, Schweigen ist Gold *gg*


 

schade, das du dich in letzter zeit so rar gemacht hast...
freu mich immer dich zu lesen...   lg.    limi  

im Tal der Tränen, wird HSXI dieses Jahr noch ausbrechen, hier wieder ein zukunftsweisendes Signal (für Leute, die dies deuten können und die nötige Geduld aufbringen):

 

Press Release Source: HealthSonix Inc.


HealthSonix Invited to Present at Small Cap Expo in New York City
Tuesday February 20, 1:00 pm ET


IRVINE, CA--(MARKET WIRE)--Feb 20, 2007 -- HealthSonix Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) announced today that it has been invited to the 2007 Small Cap Stock Expo in New York on February 28, 2007.

HealthSonix is one of only 20 emerging companies invited to present at the event, which attracts small cap experts, analysts, and members of the investment community.
The expo will feature prestigious financial professionals including guest keynote speaker Mark Robins, Head of Research for Crown Point Group. Mr. Robins is a nationally recognized small-cap stock analyst and strategist as well as a regular contributor to Forbes Magazine.

The 2007 Small Cap Stock Expo includes a formal presentation to attendees, an exhibit space for one-on-one focus and demonstration, and an exclusive interview with MoneyTV, an interactive news source for small-cap companies broadcast on cable television, the Internet at www.moneytv.net, and through downloadable podcasts.

"This event provides HealthSonix the opportunity to present the company to potential investors, financial analysts and financial experts within the small cap market," says Dieter Doederlein, Vice President of Business Development. "As we continue to focus on AquaSonix Therapy expansion plans and introduction of enSonix@home, the personal home therapy device, we are extremely excited with the opportunity to present our recent achievements and company growth at this unique event."

HealthSonix Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) is a publicly traded medical technology company. The Company's core offerings are based on proprietary, patent pending medical technologies that use sound pressure waves to administer sub-sensory micro vibration to the human body. Precisely formatted low frequency sound pressure waves are 80% effective in treating the pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive, drug free, and have no known side effects.

More information regarding HealthSonix and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

ADVERTISEMENT


Note: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

 

hey, das stehen wir durch... :-))

mfg BoMa  

die Messe am 28.02.07 und dieses Interview nun. Ich bin ja sowieso von diesem Wert überzeugt und freue mich auf den nächsten Hype (bin auch gut vorbereitet).

mms://lastream001.galaxytelevision.net/wavelit/healthsonix4.wmv

 

 

 

 

 

vom 26.02.07:

http://www.thegreenbaron.com/Webcasts.htm

unter anderem strebt man ein listing an einer seriösen Börse an (zB. Amex), ich sammle weiter auf niedrigem Niveau....

 

 

 

http://www.emergingcompany.com/volume11week8f.htm  

boma und matzel - interessantes interview.
Ich liege auch mit einer kauforder im rennen.
limi
 

@petruss ,Du mußt ja massivst gebunkert haben.Junge ,Junge  

wirklich nicht.  

irgendwie geht nix weiter!
Der händler schläft noch -
oder hat heute seinen freien tag,
oder es will keiner verkaufen...  
wünsch euch ein schönes  WE  limi  

wen es interessiert......

 

***********************************************

 

 

IRVINE, CA, Mar 05, 2007 (MARKET WIRE via COMTEX News Network) --

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S).

 

Dear HealthSonix Shareholders:

 

As we begin 2007, I thought it would be useful to take the opportunity to update you on what we accomplished in 2006 and plans for 2007. As you know, HealthSonix is a medical technology company focused on developing medical devices that aid in the fight against osteoarthritis. In the past 9 months we reached several milestones, both in North America and internationally. Here are some of the highlights:

--  HealthSonix became a public company by listing its shares on the OTC
    Market in the United States [HSXI] and on the Frankfurt Exchange, Germany
    [H7S].

--  The company secured international orders for 180k units of the
    enSonix@home device, totaling $16 million USD in gross revenues.

--  All HealthSonix products were registered with the United States Food
    and Drug Administration [FDA] were assigned a class 1 designation - the
    safest classification for medical devices - and were indicated for pain
    reduction and muscle relaxation.

--  International patent protection was filed through a Patent Cooperation
    Treaty (PCT) application to reserve the right to later file foreign patent
    applications in other key markets around the world. With this filing,
    future applications will be accorded the same effective filing date as the
    2005 US patent application.

--  World renown Rheumatologist, Dr. Edward C. Keystone joined the
    HealthSonix Medical and Scientific Advisory Board. Dr. Keystone is a
    professor of Medicine at the University of Toronto; Chairman of the
    Canadian Rheumatology Research Consortium; Associate Clinical Director of
    the Canadian Arthritis Network; founder and Board member of The Arthritis &
    Autoimmunity Research Centre of the University Health Network, one of the
    most comprehensive research centers of its kind in the world; and Senior
    Consultant, Rheumatology, at Mount Sinai.

--  HealthSonix added 3 hospital pools to its AquaSonix Therapy Centers:
    Bloorview Kids Rehab Hospital (Toronto); Baycrest (Toronto), which is one
    of the world's premier academic health sciences centers focused on aging;
    and St. Joseph's Healthcare in Hamilton, Ontario, which now also serves as
    a clinical trial site and training program for AquaSonix Therapists.

--  HealthSonix also announced the successful completion of over 200,000
    of its proprietary Sound Pressure Wave treatments, which continue to be
    successful for the treatment of chronic pain associated with arthritis,
    fibromyalgia, low back pain, and soft tissue injuries.

 

 

--  The success experienced with fibromyalgia is noteworthy. Fibromyalgia
    is a chronic disorder characterized by widespread musculoskeletal pain,
    fatigue, and multiple tender points.  People with fibromyalgia may also
    experience sleep disturbances, morning stiffness, irritable bowel syndrome,
    anxiety, and other symptoms. According to information provided by the
    American College of Rheumatology and the Arthritis Foundation, fibromyalgia
    is becoming a common disease, affecting approximately 3% of the population.
    Women are much more likely to develop fibromyalgia than men (by a ratio of
    4 to 1). The AquaSonix Therapy treatments reduce, and in some cases
    eliminate, pain and most patients report sleeping better.

This year promises to be even more exciting in terms of international growth, dictated in part by recent developments at the World Congress on osteoarthritis held in December 2006. The draft recommendations tabled at the Congress suggest that optimal management of patients with osteoarthritis of the hip and knee requires a combination of non-pharmacologic and pharmacologic modalities. Doctors and their patients have been aware of these guidelines, but were limited in their choices of "non-pharmacologic" treatments.

Today, HealthSonix offers viable non-pharmacologic treatments with its proprietary sound pressure wave modalities, and has commenced preliminary discussions with several multi-national manufacturers of prescription and over the counter drugs to conduct joint clinical trials -- with a view to address the guidelines published by the American College of Rheumatology (ACR). The objective of the joint trials will be confirm that the HealthSonix Sound Pressure Wave Therapy, in combination with the pharmacologic products, can significantly reduce pain and improve the patient's quality of life, hence should become the treatment of choice for chronic pain.

The demand for the HealthSonix products should increase exponentially over the next few years, as the population segment most susceptible to chronic pain [55 years and older] is expected to double over the next 20 years, and most pain medications that address chronic pain tend to have toxic side effects if taken in large doses and over a longer period of time. The HealthSonix Sound Pressure Wave treatments have no known side effects, are non-invasive, safe, and show an 80% success rate in reducing pain.

In summary, we feel that HealthSonix will grow significantly, on an international scale for the following reasons:

--  It's a major medical discovery in the fight against the chronic pain
    of arthritis.

--  Clinically proven efficacy in reducing pain and stiffness.

--  Intellectual property, protected, through international patent
    applications.

--  All products are registered with the FDA.

--  Growing Market segment -- as baby boomers age: no need to fight for
    market share.

--  Plans afoot to partner with major drug manufacturers for effective
    delivery of combined therapies.

--  an experienced management team that has been able to bring it all
    together.

We are also exploring various alternatives to expand our pipeline of products, and look forward to providing more detail on the progress and status of these as appropriate. I appreciate the heartfelt support everyone has shown to HealthSonix, and will be happy to further discuss the status of our progress at any time. We are committed to the continued growth and development of our Company in a manner that is meaningful for our shareholders, our future investors and the patients who we trust and believe will one day benefit from our therapies.

We thank you for your support.

 

Michael Ivezic President and CEO

 

Contact: Dieter D. Doederlein Phone: 1-(800) 622-2121

 

 

SOURCE: HealthSonix, Inc.